Table 4.
Aminoglycoside Susceptibilities Among MBL-Producing Enterobacterales
| MBL Enzyme | No. of Isolates | %S (MIC50/90 [mg/L]) | Ref. | |||
|---|---|---|---|---|---|---|
| PLZ | AMK | TOB | GENT | |||
| MBL | 37a,b | 42.1 (128/>128) |
13.5 (>32/>32) |
NR (>8/>8) |
21.6 (>8/>8) |
108 |
| 552c | N/A | 32.6 (N/A) |
N/A | 27.7 (N/A) |
156 | |
| NDM | 282d | 22.7 (N/A) |
N/A | N/A | N/A | 115 |
| 42e | 35.7 (>128/>128) |
38.1 (>128/>128) |
9.5 (>128/>128) |
14.3 (>128/>128) |
111 | |
| 277f | 52.7 (2/>128) |
52.7 (2/>64) |
20 (>16/>16) |
32 (>16/>16) |
112 | |
| VIM | 182d | 89.6 (N/A) |
N/A | N/A | N/A | 115 |
| 20g | 95 (0.5/0.5) |
90 (16/16) |
0 (16/64) |
15 (16/128) |
113 | |
| IMP | 24d | 100 (N/A) |
N/A | N/A | N/A | 115 |
Notes: Susceptible criteria: PLZ ≤2 mg/L, AMK ≤16 mg/L, TOB ≤4 mg/L, GENT ≤4 mg/L based on CLSI (AMK, TOB, GENT) and FDA interpretive criteria (PLZ). aEnterobacterales isolates carrying blaVIM and blaNDM-1 collected from European and adjacent countries during 2014–2015. bBased on EUCAST breakpoints (AMK ≤8 mg/L, TOB ≤2 mg/L, GENT ≤2 mg/L). cCollected from 33 hospitals of 5 countries of the Arabian Peninsula between 2009–2017. dCollected from global surveillance program between 2014–2017. eCollected from US, Canada, Singapore. fCollected from AR Lab Networks in the US between 2017–2018. gClinical isolates collected from single academic medical center during routine care.
Abbreviations: %S, percent susceptible; PLZ, plazomicin; AMK, amikacin; TOB, tobramycin; GENT, gentamicin; N/A, not available.